

PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Krystexxa (pegloticase)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name: Supervising Physician:	
	<u> </u>	Dhono
Member/Subscriber Number: Date of Birth:	Fax: Office Contact:	Phone:
Group Number:	NPI:	State Lic ID:
Address:	Address:	State Lie ID.
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable)	:
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.		
Q1. What diagnosis is this drug being prescribed for (pick one)?		
☐ Chronic refractory gout with hyperuricemia	Other (please specify)	
Q2. Please provide ICD code(s) for diagnosis.		
Q3. Is the patient a new start?		
☐ Yes	□No	
Q4. Does the patient have any of the following?		
☐ Two or more gout attacks in the past 12 months ☐ Serum uric acid concentration above 5 mg/dL despi ☐ Serum uric acid concentrations at or above 6 mg/dL ☐ Tophaceous gout with presence on the hands, evided quality of life	despite maximized prior therapy	significantly impacting
Q5. Will Krystexxa be used in combination with NSAIDS or colchicine for the first 6 months?		
☐ Yes	□No	



PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Krystexxa (pegloticase)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name: Supervising Physician:	
Q6. Does the patient have failure of an adequate trial of, c following? Please specify all that apply. Allopurinol 800 mg Uloric (febuxostat) 120 mg Other (please specify)		
Q7. Will use of Krystexxa be limited to 8 mg (1 mL) per 14 days?		
☐ Yes	□No	
Q8. Does the patient have a contraindication to Krystexxa therapy (e.g. G6PD deficiency)?		
☐ Yes	□No	
Q9. If for continuation, does the patient have improvement in frequency and severity of attacks? Please submit documentation		
☐ Yes	□No	
Q10. If for continuation, does the patient have serum uric acid concentrations prior to infusion are consistently less than 6 mg/d? Please submit documentation		
☐ Yes	□No	
Q11. Who is the ENTITY that will be submitting the CLAIM for the DRUG and seeking reimbursement? Pharmacy Individual prescriber Provider or specialty group Facility Other (please specify)		
Q12. Provide name and NPI of the billing entity		
Q13. Will the claim for the drug be submitted as a MEDICAL claim or PHARMACY claim (Note: If a pharmacy will be submitting a MEDICAL claim for drug reimbursement, answer MEDICAL)?		
☐ Medical	Pharmacy	
Q14. Additional Comments		



PRIOR AUTHORIZATION REQUEST FORM EOC ID: Krystoxya (pogleticase)

Krystexxa (pegloticase)

Phone: 800-728-7947 Fax back to: 866-880-4532

	acy drug benefit for your patient. Certain requests for coverage require review fax this form to the number listed above. Please note any information left
	Prescriber Name:
Patient Name:	Supervising Physician:
Prescriber Signature	Date
□ Expedited/Urgent - By checking this box and signing abov seriously jeopardize the life or health of the enrollee or the e	re, I certify that applying the standard review timeframe may nrollee's ability to regain maximum function
	ssity denial. Requesting providers may speak to a SWHP pharmacist in opportunity to help impact the decision on a request before coverag
entity named above. The authorized recipient of this information is prohibited from disc	nat is legally privileged. This information is intended only for the use of the individual or closing this information to any other party. If you are not the intended recipient, you are the contents of this document is strictly prohibited. If you have received this telecopy in